Circulating Tumor DNA Predicts Recurrence in Pancreatic Cancer
Preoperative and postoperative circulating tumor DNA (ctDNA) are crucial for predicting outcomes in pancreatic cancer patients undergoing surgery.
Newsletter
HPB & Spleen
Every new paper in this field, in your inbox.
Reducing Non-Therapeutic Laparotomies in Pancreatic Cancer Surgery
Staging laparoscopy significantly lowers the rate of unnecessary laparotomies in pancreatic cancer patients post-neoadjuvant treatment.
Laparoscopic choledocholithotripsy lower recurrence, costs than ERCP
A meta-analysis of 1,576 patients shows outcomes for managing common bile duct stones.
New Antibiotic Standard May Transform Pancreatoduodenectomy Outcomes
Broad-spectrum penicillin-based antibiotics significantly improve outcomes after pancreatoduodenectomy compared to standard care options.
Liver Transplant vs. ALPPS: Survival Similarities Uncovered
Liver transplantation (LT) and associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) yield comparable survival outcomes for colorectal liver metastases (CRLM).
Drain CRP Level on Postoperative Day 4 Predicts Pancreatic Fistulas
Drainage fluid C-reactive protein levels can help predict clinically relevant pancreatic fistulas post-pancreaticoduodenectomy.
Understanding Celiac Axis Stenosis Predictors in Pancreatoduodenectomy
Surgeons can better anticipate interventions for celiac axis stenosis (CAS) during pancreatoduodenectomy by assessing key preoperative factors.
Risk Calculator Didn’t Change Surgeons’ IPMN Decisions
A study found that a risk calculator had no significant impact on surgeons' decisions regarding surveillance for low-risk pancreatic intraductal papillary mucinous neoplasms (IPMNs).
Outcomes After Pancreatectomy for PNETs Are Similar Across Types
Pancreatectomy outcomes for pancreatic neuroendocrine tumors (PNETs) are consistent, regardless of whether they arise from sporadic cases or genetic syndromes like MEN1 and VHL.
Trends in IVC Reconstruction Show High Patency and Survival
IVC reconstruction during oncologic resections is safe, with robust mid-term outcomes.